These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19731394)

  • 41. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
    Posner MR; Colevas AD; Tishler RB
    Semin Oncol; 2000 Aug; 27(4 Suppl 8):13-24. PubMed ID: 10952434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Li SH; Lin WC; Huang TL; Chen CH; Chiu TJ; Fang FM; Huang WT; Hsu CM; Luo SD; Lai CC; Su YY; Chuang HC; Chien CY
    Head Neck; 2016 Apr; 38 Suppl 1():E844-52. PubMed ID: 25917382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)].
    Katori H; Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Tanigaki Y; Horiuchi C; Ikeda Y; Kimura M; Taguchi T; Hirose S; Yoshida T; Takahashi M; Sakuma Y; Yamamoto K; Sato N
    Nihon Jibiinkoka Gakkai Kaiho; 2005 Feb; 108(2):157-63. PubMed ID: 15765729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN).
    Kies MS
    Curr Treat Options Oncol; 2007 Jun; 8(3):252-60. PubMed ID: 17952388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TPF: a rational choice for larynx preservation?
    Calais G
    Oncologist; 2010; 15 Suppl 3():19-24. PubMed ID: 21036885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
    Posner MR; Lefebvre JL
    Br J Cancer; 2003 Jan; 88(1):11-7. PubMed ID: 12556952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
    Bardet E; Bourhis J; Cals L; Fayette J; Guigay J; Hans S; Saint-Guily JL; Lagarde F; Lallemant B; Milano G; Rolland F; Lefebvre JL
    Bull Cancer; 2009 Oct; 96(10):1013-28. PubMed ID: 19744919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
    Specenier PM; Vermorken JB
    Cancer Lett; 2007 Oct; 256(2):166-77. PubMed ID: 17673364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
    Tishler RB; Posner MR; Norris CM; Mahadevan A; Sullivan C; Goguen L; Wirth LJ; Costello R; Case M; Stowell S; Sammartino D; Busse PM; Haddad RI
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1036-44. PubMed ID: 16682134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
    Fayette J; Bonnin N; Ferlay C; Lallemant B; Ramade A; Favrel V; Zrounba P; Chabaud S; Pommier P; Poupart M; Céruse P
    Anticancer Drugs; 2013 Jul; 24(6):623-9. PubMed ID: 23542750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
    Caponigro F; Comella P; Marcolin P; Russo Spena F; Biglietto M; Cartenì G; De Lucia L; Avallone A; Gravina A; Comella G
    Cancer; 1999 Feb; 85(4):952-9. PubMed ID: 10091775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Taxotere, cisplatin, fluorouracil, and leucovorin (TPFL)as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Kamnerdsupaphon P; Chitapanarux I; Lorvidhaya V; Sumitsawan Y; Tharavichitkul E; Sukthomya V
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1869-73. PubMed ID: 19011334
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
    Haddad RI; Tishler RB; Norris C; Goguen L; Balboni TA; Costello R; Wirth L; Lorch J; Andreozzi B; Annino D; Posner MR
    J Clin Oncol; 2009 Sep; 27(27):4448-53. PubMed ID: 19704061
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
    Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
    Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.
    Tsukuda M; Mikami Y; Tanigaki Y; Katori H; Horiuchi C; Ikeda Y; Taguchi T; Ono M; Yoshida T; Sakuma Y; Aikoh K
    Int J Clin Oncol; 2004 Jun; 9(3):161-6. PubMed ID: 15221599
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Baghi M; Hambek M; Wagenblast J; May A; Gstoettner W; Knecht R
    Anticancer Res; 2006; 26(1B):585-90. PubMed ID: 16739325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Docetaxel in head and neck cancer: a review.
    Colevas AD; Posner MR
    Am J Clin Oncol; 1998 Oct; 21(5):482-6. PubMed ID: 9781605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
    Athanasiadis I; Taylor S; Vokes EE; Pelzer HJ; Rademaker A; Mittal BB; Ganzenko N; Blough R; Lester EP; Kies MS
    Cancer; 1997 Feb; 79(3):588-94. PubMed ID: 9028372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Recchia F; Saggio G; Cesta A; Amiconi G; di Blasio A; Candeloro G; Valeriani M; Tombolini V; Rea S
    Anticancer Res; 2006; 26(3B):2317-24. PubMed ID: 16821609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.